Latest News for 09/2020
18 Aug 2020
CARE (Corona Accelerated R&D in Europe) is the largest undertaking of its kind dedicated to discovering and developing urgently needed treatment options for Covid-19 The initiative is committed to a long-term understanding of the disease and development of therapies for Covid-19 and future coronavirus threats in addition to urgent efforts to repurpose existing therapies for a potential immediate response
02 Jun 2020
The University of Dundee’s Drug Discovery Unit (DDU) has received €5 million of funding to develop antiviral treatments for Covid-19 and future coronaviruses.
06 May 2020
The Universities of Glasgow and Dundee have been awarded £225,000 to rapidly screen for potential COVID-19 treatments. The project is funded by the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill & Melinda Gates Foundation, Wellcome, and Mastercard to speed up the response to the COVID-19 pandemic by funding the identification, assessment, development and scale up of treatments.
29 Jan 2020
The University of Dundee is among more than 30 international institutions joining forces to find new drug treatments for tuberculosis. The ERA4TB (European Regimen Accelerator for Tuberculosis) project is a public-private initiative dedicated to the development of drugs against tuberculosis. With a team of more than 30 organisations and a budget of over 200 million euros, ERA4TB will focus on developing a new, improved tuberculosis treatment. The partners will share their expertise, knowledge and resources to rapidly progress new candidate drugs into clinical trials.
09 Jan 2020
Researchers in the School are aiming to make a breakthrough against tuberculosis. A $3million grant from the Bill & Melinda Gates Foundation over the next three years will support the work of Professor Paul Wyatt's team. They will identify new treatment options for TB, under the banner of the `LEADS4TB’ programme.
03 Jul 2019
The Drug Discovery Unit (DDU) has announced a multi-million-pound partnership with Korean-based Bukwang Pharmaceutical Company in a bid to develop a new drug treatment for Parkinson’s disease. This announcement builds upon existing drug discovery partnerships the DDU has with Takeda and GSK. Parkinson’s disease is the second most common neurological disorder, after Alzheimer’s disease, affecting around two people in every 1000 across the population. There are around 6.1 million people worldwide and 120,000 people in the UK living with the condition.
25 Jul 2018
A new preclinical candidate drug with the potential to treat visceral leishmaniasis, one of the world’s major neglected diseases, has been discovered through a close collaboration between the University of Dundee, GSK and Wellcome.
27 Apr 2017
The University of Dundee has been awarded £7.9 million by the Wellcome Trust for a joint project with GSK (GlaxoSmithKline) to boost efforts to find new drugs to treat some of the world’s most devastating parasitic diseases including visceral and cutaneous leishmaniasis, and Chagas’ disease. These neglected diseases cause substantial suffering and an estimated 60,000 deaths annually world-wide.
07 Dec 2016
The University of Dundee has been awarded £13.6 million by Wellcome to establish a new research centre to tackle some of the world’s most devastating diseases. The Wellcome Centre for Anti-Infectives Research (CAIR) builds on world-leading work at the University’s School of Life Sciences to find new drugs to treat neglected tropical diseases such as malaria, tuberculosis and leishmaniasis.
08 Mar 2016
World-leading medicinal chemistry and biology at the Universities of Dundee (Scotland) and Cape Town (South Africa) have been allied to the industrial expertise of the Pharmaceuticals Division of Bayer (Germany), one of the world’s leading pharma companies, in an effort to develop critically needed new treatments for tuberculosis (TB). The collaboration combines some of the world’s best knowledge on TB biology, drug discovery and medicinal chemistry, with access to an industrial library of chemical compounds.